Chronic Pain News and Research

RSS

Duke Medicine researchers identify a protein critical to TMJD pain

Temporomandibular joint disorder (TMJD) is the most common form of oral or facial pain, affecting over 10 million Americans. The chronic disorder can cause severe pain often associated with chewing or biting down, and lacks effective treatments.

2 Aug 2013

Nektar completes enrollment in NKTR-102 BEACON trial in patients with metastatic breast cancer

Nektar Therapeutics (NASDAQ: NKTR) today announced that enrollment is complete in the pivotal clinical study of etirinotecan pegol (NKTR-102) in patients with metastatic breast cancer.

31 Jul 2013

Study: About 50% of fibromyalgia patients have nerve damage

About half of a small group of patients with fibromyalgia - a common syndrome that causes chronic pain and other symptoms - was found to have damage to nerve fibers in their skin and other evidence of a disease called small-fiber polyneuropathy (SFPN). Unlike fibromyalgia, which has had no known causes and few effective treatments, SFPN has a clear pathology and is known to be caused by specific medical conditions, some of which can be treated and sometimes cured.

31 Jul 2013

FDA grants orphan-drug designation to Convergence's CNV1014802 for treatment of TN

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines for the treatment of chronic pain, is pleased to announce that its novel sodium channel blocker, CNV1014802 ('802), has been granted orphan-drug designation by the US Food and Drug Administration for the treatment of trigeminal neuralgia.

30 Jul 2013

NeuroMetrix announces business and financial highlights for second quarter

NeuroMetrix, Inc. (the "Company"), a medical device company focused on the treatment of the neurological complications of diabetes, today reported business and financial highlights for the second quarter ended June 30, 2013.

25 Jul 2013

Study finds that higher-frequency electric current stimulation of the spinal cord reduces pain faster

An animal study in the August issue of Anesthesiology suggests that higher-frequency electric current stimulation of the spinal cord reduced pain quicker and better reached nerves not affected by traditionally used frequencies. A higher frequency and intensity controlled pain faster and more effectively, the study found.

25 Jul 2013

Study shows integrative approach reduces pain severity, improves mood and quality of life

An integrative approach to treating chronic pain significantly reduces pain severity while improving mood and quality of life, according to a new study from the Bravewell Practice-Based Research Network (BraveNet) published last month in BioMed Central Complementary and Alternative Medicine journal.

23 Jul 2013

Imprimis to begin IRB-approved Impracor Phase III trial for acute pain associated with OA of the knee

Imprimis Pharmaceuticals, Inc., which is focused on the commercialization of compounded drug formulations utilizing the FDA 505(b)(2) development pathway, today announced it has received IRB approval for its Phase III clinical trial protocol of its lead product candidate, Impracor.

23 Jul 2013

Study: Ultrasound waves applied to specific areas of brain appear to alter patients' moods

University of Arizona researchers have found in a recent study that ultrasound waves applied to specific areas of the brain appear able to alter patients' moods. The discovery has led the scientists to conduct further investigations with the hope that this technique could one day be used to treat conditions such as depression and anxiety.

19 Jul 2013

Cubist initiates bevenopran Phase 3 studies in patients with chronic non-cancer pain and OIC

Cubist Pharmaceuticals, Inc. today announced the initiation of Phase 3 efficacy studies of bevenopran (previously known as CB-5945) in patients with chronic non-cancer pain and opioid-induced constipation.

19 Jul 2013

Adynxx receives FDA Fast Track designation for AYX1 Injection to treat chronic pain

Adynxx, a clinical-stage pharmaceutical company developing a first-in-class platform of therapeutics to address pain at its molecular roots, announced today that the U.S. Food and Drug Administration has granted Fast Track designation to AYX1 Injection for the prevention of chronic pain.

17 Jul 2013

New study encourages pediatricians to treat the cause, not the symptoms

Researchers at Holland Bloorview Kids Rehabilitation Hospital have found that more than 25 percent of children with cerebral palsy seen by physicians have moderate to severe chronic pain, limiting their activity. Findings indicate that pediatricians should be aware of chronic pain in this group and try to identify and treat its underlying causes.

16 Jul 2013

Orlando Health and UF health partner to expand neurosurgery program

Orlando Health and the University of Florida department of neurosurgery have partnered to expand the neurosurgery program at Orlando Health with the opening of a specialized practice, UF Health Neurosurgery — Orlando Health.

10 Jul 2013

Acorda Therapeutics acquires two neuropathic pain management assets from NeurogesX

Acorda Therapeutics, Inc. today announced that it has acquired two neuropathic pain management assets from NeurogesX, Inc. Qutenza is approved by the U.S. Food and Drug Administration for the management of neuropathic pain associated with postherpetic neuralgia.

9 Jul 2013

Action Medical Research funds three new Research Training Fellowships

Action Medical Research, the UK-wide charity funding vital research to help sick and disabled babies and children, has today announced it is funding three new Research Training Fellowships worth more than £470,000.

9 Jul 2013

State highlights: Docs prescribe narcotics too often, CDC chief says; Fla. hospices get close scrutiny; Calif. Medi-Cal provider rate bump delayed

The nation's top public health official on Tuesday sharply criticized the widespread treatment of aches and pains with narcotics, saying that doctors are prescribing such drugs too soon, too often and for too long -- putting patients at risk of addiction and overdose. Dr. Tom Frieden, director of the U.S. Centers for Disease Control and Prevention, said that doctors are relying on these powerful drugs to treat chronic pain when physical therapy, exercise and other remedies would be safer and in many cases more effective (Girion and Glover, 7/2).

4 Jul 2013

First Edition: July 3, 2013

Today's headlines detail the Obama administration announcement that it would delay the health law rule requiring businesses provide insurance to workers.

3 Jul 2013

UH receives NIDA grant to study transdiagnostic CBT to address tobacco cessation

According to the Centers for Disease Control and Prevention, tobacco use continues to be the leading preventable cause of death in the U.S. resulting in more than 440,000 premature deaths a year. An additional 25 million smokers will most likely die of a smoking related illness.

27 Jun 2013

Physician’s unfavorable attitudes about opioid drugs linked with lower rates of prescribing

According to a study of physicians' attitudes about pain drugs published in The Journal of Pain, negative physician attitudes about opioid medications are closely associated with lower rates of prescribing and more favorable attitudes are linked with higher prescribing levels.

26 Jun 2013

Study explores analgesic activity of ceftriaxone in humans

A single dose of the antibiotic ceftriaxone given for antimicrobial prophylaxis prior to surgery enhanced patient pain thresholds after the procedure, according to a study published in The Journal of Pain, the peer review publication of the American Pain Society.